Ultra Nuclease

UltraNuclease is a genetically engineeredendonuclaese derived from Serratia marcescens,which is capable of degrade DNA or RNA,either double or single stranded, linear or circular under a wide range of condition,completely degrade nucleic acids into 5’-monophosphate oligonucleotides with 3-5base length. After genetic engineering modification, theproduct was fermented, expressed, and purifiedin Escherichia coli (E. coli), which reducestheviscosity of cell supernatant and cell lysate inscientific research, but also improve the purification efficiency and functional research ofprotein. It can also be used in the gene therapy,virus purification, vaccine production, proteinand polysaccharide pharmaceutical industry as a host residue nucleic acid removal reagent.

Product features

Storage conditions

≤0°C transportation；-25~-15°C Storage，2 years validity (avoid freezing-thawing).

Unit Definition

The amount of enzyme used to change the absorption value of △A260 by 1.0 within 30min at 37 °C, pH 8.0, equivalent to digested 37μg salmon sperm DNA by cutting into oligonucleotides, was defined as an active unit(U).

Quality control

Residual Host-cell Protein: ELISA kit

•Protease Residues: 250KU/mL UltraNuclease reacted with substrate for 60min, no activity was detected.

•Bacterial Endotoxin: LAL-Test, Pharmacopoeia of the People ’s Republic of China Volume 4 (2020 Edition) gel limit test method. General Rules (1143).

•Bioburden: Pharmacopoeia of the People ’s Republic of China Volume 4 (2020 Edition)— General 

Rules for Sterility Test (1101), PRC National Standard, GB 4789.2-2016.

•Heavy Metal: ICP-AES, HJ776-2015.

Operation

UltraNuclease activity was significantly inhibited when SDS concentration was over 0.1% or EDTA

concentration was over 1mM.Surfactant Triton X- 100, Tween 20 and Tween 80 had no effect on nuclease

properties when the concentration was under 1.5%.

 Usage and Dosage

• Remove exogenous nucleic acid from vaccine products, reduce the risk of residual nucleic acid toxicity and improve product safety.

• Reduce the viscosity of feed liquid caused by nucleic acid, shorten processing time and increase protein yield.

• Remove the nucleic  acid  which  wrapped particle (virus, inclusion body, etc.), which is conducive 

to the release and purification of the particle.

• Nuclease treatment can improve the resolution and  recovery of the sample for column chromatography, electrophoresis and blotting analysis.

• In gene therapy, nucleic acid is removed to obtain purified adeno-associated viruses.